Cerebral protective effects of VA-045, a novel apovincaminic acid derivative, in mice.
The cerebral protective effects of VA-045, a novel apovincaminic acid derivative, were investigated in mice under conditions of normobaric hypoxia, histotoxic anoxia by potassium cyanide (KCN), and complete ischemia. VA-045 and thyrotropin releasing hormone (TRH) showed a significant protective effect on normobaric hypoxia. The duration of action of the protective effect of VA-045 was longer than that of TRH. VA-045 but not TRH significantly prolonged the survival time following administration of KCN. VA-045 and TRH showed a positive effect on complete ischemia, and the duration of the protective effect of VA-045 was longer than that of TRH. Beneficial effects of VA-045 for treating cerebral hypoxia, anoxia and ischemia will be discussed.
Nihon Bioresearch Center Inc., Gifu, Japan.
S
S
Yamada
K
K
Yamaguchi
S
S
Okuyama
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D000860:Hypoxia / Q000188:drug therapy; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D013973:Thyrotropin-Releasing Hormone / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C081044:2-(nitrooxy)ethyl apovincaminate; D013973:Thyrotropin-Releasing Hormone